Eritoran

also known as E5564 · eritoran tetrasodium

Small molecule targets TLR4 via inhibition

Developed for: infectious disease with sepsis · pneumonia
Investigated by: Australian and New Zealand Intensive Care Research Centre · Berry Consultants · Eisai Inc. · Global Coalition for Adaptive Research · Intensive Care National Audit & Research Centre · Medical Research Institute of New Zealand
+6 more
· Nat Intensive Care Surveillance - MORU · National University Hospital, Singapore · St. Marianna University School of Medicine · UMC Utrecht · Unity Health · University of Pittsburgh Medical Center

today NCT02735707 · Ph 3 NCT00334828 · Ph 3

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT02735707	Apr 2016 → Feb 2026 overdue	pneumonia	UMC Utrecht	Recruiting	No outcome recorded
Phase 3	NCT00334828	Jun 2006 → Jan 2011	infectious disease with sepsis	Eisai Inc.	Completed	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT02321111 Comparator	Jan 2015 → Sep 2018	—	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 2	NCT02267317 Comparator	Jan 2015 → Sep 2018	—	The University of Texas Health Science Center at San Antonio	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	eritoran	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00334828 ↗ 3 NCT02267317 ↗ NCT02735707 ↗ NCT02321111 ↗
Known as	E5564	“E5564 = Eritoran” NCT02267317 ↗
Known as	eritoran tetrasodium	“Patients with severe sepsis (n = 1961) were randomized and treated within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course of either eritoran...” PMID 23512062 ↗ Mar 2013
Action	Inhibit	“blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor” PMID 23512062 ↗ Mar 2013
Modality	Small molecule	“Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor.” PMID 23512062 ↗ Mar 2013
Route	Intravenous	“Intravenous infusion at a total dose of 105 mg.” NCT00334828 ↗
Target	TLR4	“antagonist of MD2-TLR4” PMID 23512062 ↗ Mar 2013